Dr Reddy’s Laboratories (RDY) has released an update.
Dr. Reddy’s Laboratories has announced the acquisition of the global Nicotine Replacement Therapy (NRT) portfolio from Haleon plc, including the leading brand Nicotinell® and other local brands, enhancing its consumer healthcare footprint. The GBP 500 million deal, which is margin-accretive with steady sales, is funded through internal accruals and is expected to close in the fourth quarter of 2024. This strategic move is part of Dr. Reddy’s expansion into consumer healthcare, complementing its generics and biosimilars business and marking a significant step towards the company’s long-term goals.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
